Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000162828021001364/novo-b20xf12x31x20.htm
June 2022
June 2022
June 2022
June 2022
June 2022
June 2022
May 2022
May 2022
May 2022
May 2022
Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/353278/000162828021001364/novo-b20xf12x31x20.htm
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Novo Nordisk A S.
Novo Nordisk A S's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Novo Nordisk A S provided additional information to their SEC Filing as exhibits
Ticker: NVO
CIK: 353278
Form Type: 20-F Annual Report
Accession Number: 0001628280-21-001364
Submitted to the SEC: Wed Feb 03 2021 2:34:50 PM EST
Accepted by the SEC: Wed Feb 03 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations